DESCRIBE the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy.
|
|
|
|
|
|
DISCUSS the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway.
|
|
|
|
|
|
REVIEW outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD
|
|
|
|
|
|